Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance | Zendy

Kristina B. Emdal | Zendy; Nicolàs Palacio-Escat | Zendy; Caroline Wigerup | Zendy; Akihiro Eguchi | Zendy; Helén Nilsson | Zendy; Dorte B. BekkerJensen | Zendy; Lars Rönnstrand | Zendy; Julhash U. Kazi | Zendy; Alexandre Puissant | Zendy; Raphaël Itzykson | Zendy; Julio Sáez-Rodríguez | Zendy; Kristina Masson | Zendy; Peter BlumeJensen | Zendy; Jesper V. Olsen | Zendy

Open Access

Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance

Author(s) -

Kristina B. Emdal,

Nicolàs Palacio-Escat,

Caroline Wigerup,

Akihiro Eguchi,

Helén Nilsson,

Dorte B. BekkerJensen,

Lars Rönnstrand,

Julhash U. Kazi,

Alexandre Puissant,

Raphaël Itzykson,

Julio Sáez-Rodríguez,

Kristina Masson,

Peter BlumeJensen,

Jesper V. Olsen

Publication year - 2022

Publication title -

cell reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.264

H-Index - 154

eISSN - 2639-1856

pISSN - 2211-1247

DOI - 10.1016/j.celrep.2022.111177

Subject(s) - phosphoproteomics , context (archaeology) , protein kinase b , foxo3 , proteome , cancer research , phosphorylation , myeloid leukemia , biology , computational biology , bioinformatics , microbiology and biotechnology , protein phosphorylation , protein kinase a , paleontology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research